The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Reform agenda puts China's economic superagency under scrutiny

Mon, 15th Jul 2013 21:02

By Alexandra Harney

SHANGHAI, July 16 (Reuters) - Behind China's twoinvestigations into irregular pricing of infant formula andpharmaceuticals announced this month is one powerful institutionand its struggle for relevance as Beijing attempts a transitionto a more consumption-led economy.

The investigations have entangled big foreign companiesincluding Danone SA, Nestle SA andGlaxoSmithKline Plc. But some analysts say there may besomething deeper at work - jockeying over the direction ofpolicy in the world's second largest economy in the years ahead.

The National Development and Reform Commission (NDRC),Beijing's economic superagency, sets policy for strategicindustries, approves big investments, mergers and acquisitions,and has the authority to influence prices for everything fromliquor to gasoline.

Its powers are so sweeping that it is often called the"little State Council".

But in recent months, as President Xi Jinping and Premier LiKeqiang have begun an attempt to steer China's economy away fromits reliance on state-led investment towards a moreconsumer-focused model, academics and even senior officials havebegun to publicly cast doubt on the NDRC's role.

While the NDRC has always had a price-setting role, itsdecision to launch high profile predatory pricing probes intoinfant formula and drugs now could be a bid by the commission toprove its usefulness as a regulator.

"On a fundamental level, the NDRC is scrambling to show thatit has something to contribute," says Barry Naughton, professorat the University of California, San Diego, and a specialist inChina's economy.

SHIFTING PRIORITIES

That the main economic policy body in the fastest-growingmajor economy over the past decade might feel the need to shoreup its position says much about the debate raging among Chinesepolicymakers. In key areas, the new leaders are trying to shiftChina's priorities in ways that represent a challenge to theNDRC's traditional dominance.

Evidence that dominance could be under threat includes thefact that Premier Li made the reduction of bureaucraticapprovals - one of the NDRC's main roles - a key plank of hisreform plan announced in March.

In May, Li also rejected a 40 trillion yuan ($6.5 trillion)urbanisation plan that the NDRC had proposed, sources familiarwith the matter told Reuters, although the commission deniesthis.

Xi and Li remain committed to urbanisation, but the push nowis "less about building stuff", says Arthur Kroeber, managingdirector of GaveKal Dragonomics Research, and more about helpingmigrants live "more fully-fledged urban lives".

Reducing bureaucratic red tape - such as the NDRC approvalsprocess - is another way the new administration would like toshrink the role of the state in the economy.

There are also concerns among academics about the NDRC as aninstitution. Founded in 1952 as the State Planning Commission,it is deeply rooted in China's command economy past, even as itcrafts policies for its mostly capitalist present.

Part of the debate is about whether, through its investmentapproval function, the NDRC is allocating resources asefficiently as possible, says Shi Lei, professor of economics atFudan University. Overcapacity plagues many industries in China.

With so much power concentrated in one institution,corruption is another worry - Liu Tienan, former NDRC vicechairman, is under investigation over allegations he took bribesto help a businessman defraud banks.

REGULATORY ROLE

The NDRC is no stranger to controversy. It has facedchallenges to its power before and has found ways to survive andeven increase its influence.

Indeed, this month's drugs and formula investigations couldwell be a sign that the NDRC is adapting to the new mood inBeijing by strengthening its role as a regulator.

Especially since the 2011 introduction of regulationsgoverning its role in implementing the 2008 Anti-Monopoly Law,the NDRC has been stepping up its investigations into pricingpractices.

In March, it imposed a 449 million yuan fine on two domesticliquor firms for setting minimum resale prices and a 10 millionyuan fine on eight real estate companies for misleadingcustomers and violating pricing regulations.

In January, it found six foreign LCD manufacturers guilty ofprice fixing and fined them 353 million yuan.

Few sectors pack the symbolic punch of infant formula, bothfor Chinese consumers and the government. Since 2008, whenmelamine in infant formula killed six babies and sickened300,000 others, the infant formula industry has epitomized thetrade-off between rapid economic growth and health and safety.

Driving down prices also supports Beijing's efforts to shiftthe economy away from a reliance on exports and investmenttoward a greater dependence on consumption. Drugs and infantformula are both commonly perceived as too expensive.

"Every time price reductions are made, it's mainly a publicrelations exercise," said Zhou Zhang, an analyst at ChinaMerchant Securities. "The NDRC trumpets how big reductions willbe, but when it comes down to it, prices only fall a bit. TheNDRC's main consideration is public relations."

The NDRC did not respond to a request for comment. Oneperson with knowledge of the NDRC investigations said that theywere being conducted at an unusually rapid pace.

The infant formula investigation also appears to cover notcollusion among companies, but how the retail prices for theseproducts are set - an issue where China's laws differ from thosein other countries, including the United States.

All of the infant formula companies targeted have reducedprices in China since the NDRC announced its investigation.

That might be good for consumers in the short term, butScott Kennedy, director of the Research Center for ChinesePolitics & Business at Indiana University, questioned the NDRC'scredentials as a consumer watchdog, given its central role inChina's export- and investment-led expansion of the past twodecades.

"This is an economy built by, for and of industry," he said.

More News
Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.